Unknown PHASE2 INTERVENTIONAL 2-arm NCT00544791

The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment (MCI)

The Effect of Melatonin on Memory and Other Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment (MCI): A Placebo- Controlled Study.

Sponsor: Assaf-Harofeh Medical Center

Conditions Mild Cognitive Impairment (MCI)

Interventions melatonin placebo like melatonin tablets

Updated 6 times since 2017 Last updated: Oct 15, 2007 Started: Oct 31, 2007 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Mild Cognitive Impairment (MCI) and is currently ongoing. Assaf-Harofeh Medical Center leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assaf-Harofeh Medical Center
Neurim Pharmaceuticals Ltd.

Data source: Assaf-Harofeh Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ẕerifin, Israel